New risk score could tailor therapy for aggressive myeloma
NCT ID NCT07045168
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study aims to personalize treatment for people newly diagnosed with multiple myeloma who have an extra copy of chromosome 1q, a marker of higher risk. Researchers will use a scoring system based on factors like disease stage and lab results to classify patients into low, intermediate, or high-risk groups. Each group will then receive a tailored treatment plan, with the goal of improving how well the cancer responds and reducing the chance of it coming back.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
risk-scoring model (a tool to classify patients into risk groups based on clinical features, guiding treatment intensity)
What this could lead to
If successful, this could lead to more personalized and effective treatment plans for multiple myeloma patients with +1q, potentially improving survival and reducing side effects.
What could go wrong
This is an early-stage, non-randomized study with 200 participants, so results may not apply to all patients. The risk model may not accurately predict outcomes, and individual responses to treatment can vary.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Hospital of Jilin University
Changchun, Jilin, 130021, China